| Site Map | Contact Us | |  |
Print Page | |||
| Celgene Corporation and its employees are working relentlessly to provide solutions for unmet medical needs in cancer and debilitating inflammatory diseases. In Europe, Celgene currently has three drugs registered for the treatment of the haematological cancers: multiple myeloma and myelodysplastic syndromes. There are more than 200 ongoing clinical trials at major medical centres worldwide using innovative compounds from Celgene. These investigational compounds are being actively studied in clinical trials for patients with incurable haematological cancers, solid tumour cancers and inflammatory diseases. By utilising the latest advances in molecular and cellular research to develop novel therapies that target the mechanisms of disease at their source, Celgene is making potentially life-saving treatments a reality for the millions of patients around the world fighting cancer and other debilitating diseases. Information regarding Celgene sponsored clinical trials can be found on > clinicaltrials.ifpma.org Explore: Who we are Our Corporate History or Contact Us
This site is intended for persons located in Norway. Click on the following links to be redirected to other Celgene websites:
|